Arquivo

Página 2/3 1 2 3

Zambon launches Xadago® (safinamide) in Spain for patients with mid-to late-stage Parkinson’s disease
22 fevereiro 2016
Zambon launches Xadago® (Safinamide) in Italy for patients with mid- to late-stage Parkinson’s disease
29 fevereiro 2016
Seqirus and Zambon enter into a partnership for Parkinson’s disease product in Australia and New Zealand
10 janeiro 2017
CHMP recommends Approval of Xadago TM (safinamide) to treat Parkinson´s disease in the EU
19 dezembro 2015
Zambon invests in innovation acquiring Eratech
06 agosto 2015
Zambon expands in Europe acquiring Nigaard
14 julho 2015
50 anos de Fluimucil (N-Acetilcisteína, NAC)
23 junho 2015
Zambon launches Xadago® (safinamide) for patients with mid- to late-stage Parkinson’s disease in Germany
15 maio 2015
CHMP recommends Approval of XadagoTM (safinamide) to treat Parkinson´s disease in the EU
19 dezembro 2014
Mucosidade à solta em Lisboa e no Porto
21 novembro 2013

Página 2/3 1 2 3

Categorie

Newron re-submits US NDA for Xadago® (safinamide)
22 setembro 2016
Roberto Tascione new Ceo of Zambon
16 setembro 2016
Zambon launches Xadago® (safinamide) in Norway for patients with mid- to late-stage Parkinson's disease
01 setembro 2016

ZAMBON

PHARMA
Zambon SpA

FINE CHEMICALS
Zach System

RESEARCH VENTURE
Zcube

EUROPE

UK
Nordics

ASIA

SOUTH AMERICA

Ver más

Zambon Produtos Farmacêuticos, Lda. - ©2017, Todos os direitos reservados.
ZAMBON Prod. Farm., Lda. | Rua Comandante Enrique Maya, nº1 | 1500 - 192 Lisboa | Portugal | T. +351 217 600 952/4 | F. +351 217 600 975